Segmented RNA Reassortment

Ruth Bishop, Paul Offit, Stanley Plotkin, and the Bovine-Human Rotavirus Chimeras

In 1973 at the Royal Children's Hospital in Melbourne, Australia, microbiologist Ruth Bishop, gastroenterologist Geoffrey Davidson, and electron microscopists Ian Holmes and Brian Ruck examined thin sections of duodenal mucosal biopsies taken from nine infants hospitalized with acute winter gastroenteritis. Under the transmission electron microscope, the pathogen that had eluded bacteriologists for decades appeared inside dilated cisternae of the enterocyte endoplasmic reticulum: 70-nanometer triple-layered icosahedral virions resembling miniature wagon wheels with radiating spikes and a smooth rim. Named rotavirus from the Latin rota, this non-enveloped double-stranded RNA virus infected virtually every child before age five. It destroyed mature absorptive villous enterocytes in the small intestine and secreted a viral enterotoxin (NSP4) that opens calcium-activated chloride channels, causing profuse watery diarrhea that killed more than 500,000 infants annually across low-income nations.

Because rotavirus replicates exclusively within the superficial enterocytes of the small intestinal villi without systemic viremia, parenteral killed vaccines elicit serum $\text{IgG}$ that fails to reach the duodenal lumen in sufficient quantity to prevent mucosal damage. Effective prophylaxis required an orally administered live-attenuated virus capable of replicating quietly in the infant gut and inducing local dimeric secretory $\text{IgA}$. Beginning in the 1980s at the National Institutes of Health, Albert Kapikian developed the first licensed oral rotavirus vaccine, RotaShield, by exploiting the host-range restriction of a rhesus macaque rotavirus (RRV) combined with three rhesus-human reassortant strains covering human serotypes G1, G2, G3, and G4. Licensed in August 1998 and administered to roughly one million American infants, RotaShield was withdrawn in October 1999 after the Vaccine Adverse Event Reporting System (VAERS) and case-control studies detected a clustering of intussusception—a mechanical bowel obstruction in which a segment of the distal ileum telescopes into the adjacent cecum. Intussusception occurred in roughly 1 out of every 10,000 vaccinated infants during the first week after the initial dose, driven by vigorous simian viral replication and lymphoid hyperplasia in the infant Peyer's patches.

A parallel research program begun in 1980 at the Children's Hospital of Philadelphia (CHOP) and the Wistar Institute by virologists Fred Clark, Paul Offit, and Stanley Plotkin solved this safety bottleneck by pairing a far gentler animal host-range parent with the unique genetics of the Reoviridae family. Unlike single-stranded RNA viruses such as polio or measles whose genomes consist of a single continuous molecule, the rotavirus core encloses eleven discrete segments of double-stranded RNA (dsRNA), numbered segment 1 through segment 11 by decreasing molecular weight on polyacrylamide gel electrophoresis. Each dsRNA segment functions as an independent monocistronic gene encoding a single structural (VP1–VP4, VP6, VP7) or nonstructural (NSP1–NSP5) viral protein. Crucially, protective neutralizing antibodies against human rotavirus target the two proteins that form the outermost capsid layer: the glycoprotein VP7 (which defines G serotypes) and the protease-cleaved spike protein VP4 (which defines P genotypes).

In 1981, Clark, Plotkin, and Offit isolated a bovine rotavirus strain designated WC3 from a scouring calf on a dairy farm in Chester County, Pennsylvania. Because bovine WC3 had evolved to replicate in the gastrointestinal tract of cattle, it exhibited natural host-range attenuation in human infants. When swallowed by babies, WC3 replicated poorly in human duodenal enterocytes, caused neither fever nor diarrhea, and did not trigger intestinal lymphoid swelling. However, its bovine outer capsid proteins (G6P7[5]) were antigenically too distant from circulating human strains (G1–G4, P1A[8]) to confer consistent cross-protection on its own.

To combine the benign intestinal replication of the bovine WC3 backbone with the neutralization epitopes of human rotaviruses, Offit, Clark, and Plotkin co-infected cultured monkey kidney (Vero) cells simultaneously with the bovine WC3 parent and a human clinical isolate. Inside a doubly infected cell, newly synthesized bovine and human dsRNA segments packaged randomly into assembling viral cores across $2^{11} = 2,048$ theoretical combinations. By adding hyperimmune anti-bovine-VP7 antiserum to the culture dishes to neutralize progeny virions wearing a cow outer coat, the team selectively isolated monoreassortant chimeras. Each chimera carried ten internal genes from the attenuated bovine WC3 strain plus a single RNA segment encoding the human G1, G2, G3, G4 (VP7), or P1A[8] (VP4) surface antigen. Formulated as the pentavalent oral vaccine RotaTeq and evaluated in the 2001–2005 Rotavirus Efficacy and Safety Trial (REST) across 70,301 infants in eleven countries—alongside GlaxoSmithKline's 63,225-infant trial of the monovalent human strain Rotarix—the bovine-human reassortants showed zero elevated risk of intussusception while reducing severe rotavirus gastroenteritis by 98 percent and hospitalizations by 94.5 percent.